Adjuvant immunotherapies are substances that are either used alone, or in combination with other immunotherapies, to improve their response.
How do adjuvant immunotherapies work?
Some adjuvant immunotherapies use ‘ligands’ to boost immune responses. Ligands are molecules that can bind to protein receptors on cells, with names such as ‘toll-like receptors (TLRs)’. These are molecules that are used to boost the body’s immune response. They have shown some effectiveness in brain, kidney, lung, colon, pancreatic, prostate, ovarian and breast cancer.
Checkpoint inhibitors come under this broad category.
Adjuvant immunotherapies hope to improve responses to cancer vaccines that use T-cells or other immune cells.
Support and Information Services
Research & Clinical Trials Information
You can also join our active online community.
In this section
Share your experiences and help create change
By taking part in our Improving Brain Tumour Care surveys and sharing your experiences, you can help us improve treatment and care for everyone affected by a brain tumour.